How and When to Monitor a Patient Treated with Low Molecular Weight Heparin

 

 Buy Article Permissions and Reprints

ABSTRACT

Low molecular weight heparins (LMWHs) are as efficient as unfractionated heparin (UFH) for prevention and treatment of thromboembolism. There is no evidence that monitoring the dose improves the clinical efficacy. In contrast, any overdosage increases the risk of hemorrhage. Because renal function plays a significant role in the elimination of LMWH, curative treatment should be monitored with an anti-factor Xa assay in patients presenting renal insufficiency, in the elderly, and in patients presenting an increased hemorrhagic risk. It is advisable to sample the patient at peak activity (3 to 5 hours after the subcutaneous [sc] administration) and to target the mean anti-factor Xa activity that was found efficient and safe in the clinical trial. This target is different for each LMWH and each dose regimen.

REFERENCES

• 1 Leizorovicz A, Simmonneau G, Decousus J, Boissel J P. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis.  BMJ . 1994;  309 299-304
  PubMedGoogle Scholar
• 2 Lensing A WA, Prins M H, Davidson B L, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins.  Arch Intern Med . 1995;  155 601-607
  CrossrefPubMedGoogle Scholar
• 3 Simmonneau G, Sors H, Charbonnier B. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism.  N Engl J Med . 1997;  337 663-669
  CrossrefPubMedGoogle Scholar
• 4 The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.  N Engl J Med . 1997;  337 657-662
  CrossrefPubMedGoogle Scholar
• 5 Swahn E, Wallentin L. Low molecular weight heparin (Fragmin) during instability in coronary artery disease (FRISC).  Am J Cardiol . 1997;  80 25-29
  CrossrefPubMedGoogle Scholar
• 6 Klein W, Buchwald A, Hillis S E. Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in unstable coronary disease study (FRISC).  Circulation . 1997;  96 61-68
  PubMedGoogle Scholar
• 7 Cohen M, Demers C, Gurfinkel E P. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease.  N Engl J Med . 1997;  337 447-452
  CrossrefPubMedGoogle Scholar
• 8 Levine M, Gent M, Hirsh J. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.  N Engl J Med . 1996;  334 677-681
  CrossrefPubMedGoogle Scholar
• 9 Koopman M MW, Prandoni P, Piovella F, Ockelford P A. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home.  N Engl J Med . 1996;  334 682-687
  CrossrefPubMedGoogle Scholar
• 10 Alhenc-Gelas M, Le Guernic J, Vitoux J F. Adjusted versus fixed doses of the low-molecular-weight heparin Fragmin℗ in the treatment of deep vein thrombosis.  Thromb Haemost . 1994;  71 698-702
  PubMedGoogle Scholar
• 11 Carter C J, Kelton J G, Hirsh J. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits.  Blood . 1992;  59 1239-1245
  PubMedGoogle Scholar
• 12 Leizorovicz A, Simmonneau G, Decousus H. Comparison of low molecular weight heparin and unfractionated heparin in the treatment of DVT: a metaanalysis.  Thromb Haemost . 1993;  69 647(Abst)
  PubMedGoogle Scholar
• 13 Thomas D P. Does low molecular weight heparin cause less bleeding.  Thromb Haemost . 1997;  78 1422-1425
  PubMedGoogle Scholar
• 14 Boneu B, Caranobe C, Saivin S, Dol F, Sié P. Pharmacokinetics of heparin and of dermatan sulfate: clinical implications.  Adv Exp Med Biol . 1992;  313 237-247
  PubMedGoogle Scholar
• 15 Goudable C, Saivin S, Houin G. Pharmacokinetics of a low molecular weight heparin (Fraxiparin℗) in various stages of chronic renal failure.  Nephron . 1991;  59 543-545
  PubMedGoogle Scholar
• 16 Cadroy Y, Pourrat J, Baladre M F. Delayed elimination of enoxaparin in patients with chronic renal insufficiency.  Thromb Res . 1991;  63 385-390
  CrossrefPubMedGoogle Scholar
• 17 Mismetti P, Laporte-Simitsidis S, Navarro C. Aging and venous thromboembolism influence of pharmacodynamics of the anti-Xa and anti-IIa activities of a low molecular weight heparin (nadroparin).  Thromb Haemost . 1998;  79 1162-1165
  PubMedGoogle Scholar
• 18 Siguret V, Pautas E, Fevrier M. Elderly patients treated with tinzaparin (Innohep℗) administered once daily (175 anti-Xa U/kg): anti-Xa and anti-IIa activities over 10 days.  Thromb Haemost . 2000;  84 800-804
  PubMedGoogle Scholar
• 19 Hemker H C, Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential.  Thromb Haemost . 1995;  74 134-138
  PubMedGoogle Scholar
• 20 Boneu B, Faruel-Bille V, Pierrejean D, Gabaig A M. Limitations of the chronometric assays to determine plasma antifactor Xa activity during low molecular weight heparin therapy.  Nouv Rev Fr Hematol . 1991;  33 287-291
  PubMedGoogle Scholar
• 21 Barrowcliffe T W, Curtis A, Johnson E, Thomas D P. An international standard for low molecular weight heparin.  Thromb Haemost . 1988;  60 1-7
  PubMedGoogle Scholar
• 22 Sié P, Aillaud M F, de Prost D. Measurement of low molecular weight heparin ex vivo activities in clinical laboratories using various anti-Xa assays, interlaboratory variability and requirement of an agreed low molecular weight heparin standard.  Thromb Haemost . 1987;  58 879-883
  PubMedGoogle Scholar
• 23 Boneu B, Navarro C, Cambus J P. Pharmacodynamics and tolerance of two nadroparin formulations (10250 and 20500 anti-Xa IU/ml^-1) delivered for 10 days at therapeutic dose.  Thromb Haemost . 1998;  79 338-341
  PubMedGoogle Scholar
• 24 The DVTENOX Study Group. Markers of hemostatic system activation in acute deep venous thrombosis-evolution during the first days of heparin treatment.  Thromb Haemost . 1993;  70 909-914
  PubMedGoogle Scholar